Interferon-β-Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring
- PMID: 34317680
- PMCID: PMC8311374
- DOI: 10.1016/j.jaccas.2021.02.005
Interferon-β-Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring
Abstract
A 48-year-old woman who had been receiving long-term interferon-β for 8 years for multiple sclerosis developed drug-induced World Health Organization group I pulmonary arterial hypertension. Triple therapy for pulmonary arterial hypertension and suspension of interferon-β led to improvement from a high-risk to low-risk state and improvement in exercise hemodynamics, including vascular distensibility, and right ventricle-pulmonary artery coupling. (Level of Difficulty: Advanced.).
Keywords: 6MWD, 6-min walk distance; BNP, B-type natriuretic peptide; BP, blood pressure; CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise test; Dlco, diffusion capacity of carbon monoxide; ET, endothelin; IFN, interferon; MS, multiple sclerosis; NYHA, New York Heart Association; PA, pulmonary arterial; PAH, pulmonary arterial hypertension; RHC, right-sided heart catheterization; RV, right ventricular; exercise; pulmonary hypertension; right ventricle.
© 2021 The Authors.
Conflict of interest statement
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures




References
-
- Badesch D.B., Raskob G.E., Elliott C.G. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137:376–387. - PubMed
-
- Savale L., Sattler C., Günther S. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J. 2014;44:1627–1634. - PubMed